Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 129-56-6 | Product Number: A2548
Anthra[1,9-cd]pyrazol-6(2H)-one
Purity: >95.0%(HPLC)
Synonyms:
- Dibenzo[cd,g]indazol-6(2H)-one
- SP 600125
Product Documents:
Size | Unit Price | Belgium | Japan* | Quantity |
---|---|---|---|---|
25MG |
124,00 €
|
Contact Us | 7 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
Product Number | A2548 |
Purity / Analysis Method | >95.0%(HPLC) |
Molecular Formula / Molecular Weight | C__1__4H__8N__2O = 220.23 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Condition to Avoid | Heat Sensitive |
CAS RN | 129-56-6 |
Reaxys Registry Number | 746890 |
PubChem Substance ID | 253659651 |
MDL Number | MFCD00022289 |
Specifications
Appearance | Light yellow to Yellow to Green powder to crystal |
Purity(HPLC) | min. 95.0 area% |
Properties (reference)
Melting Point | 282 °C |
GHS
Related Laws:
EC Number | 204-955-6 |
RTECS# | CB4585000 |
Transport Information:
HS Number | 2933998090 |
Application
LRRK2 Inhibitory Effect of SP600125
This product (SP600125) is an inhibitor of Jun N-terminal kinase (JNK), which is a stress-activated protein kinase that can be induced by inflammatory cytokines, bacterial endotoxin, osmotic shock, UV radiation, and hypoxia. In addition, there is a report that SP600125 inhibits LRRK2 (Leucine-rich repeat kinase 2) -G2019S, which is a promising therapeutic target for the treatment of Parkinson's disease, in the low micro-molar range. (The product is for research purpose only.)
References
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
- Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models (a review)
Application
Apoptosis
References
- PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells
- Nongenotropic, anti-apoptotic signaling of 1α,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes: MEDIATION BY Src, PHOSPHATIDYLINOSITOL 3-, AND JNK KINASES
Application
c-Jun N-Terminal Kinase (JNK) Inhibitor
References
- 1)SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
- 2)Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125
- 3)A mammalian scaffold complex that selectively mediates MAP kinase activation
- 4)Scaffold proteins of MAP-kinase modules
- 5)Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1
PubMed Literature
Articles/Brochures
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.